Literature DB >> 86474

Profiles of serum complement in patients with hepatobiliary diseases.

B J Potter, E Elias, P M Fayers, E A Jones.   

Abstract

CH50 and the concentrations of C3, C4, C1 INH and factor B have been measured in sera from 34 control subjects and 178 patients with various hepatobiliary diseases, including primary biliary cirrhosis (PBC), chronic active hepatitis (CAH), cryptogenic cirrhosis (CC), alcoholic liver disease (ALD), Wilson's disease (WD), large duct biliary obstruction (LDBO) and viral hepatitis (VH). CH50 was decreased in CAH and CC. C3 was increased in PBC, LDBO and VH and decreased in CAH and CC. C4 was decreased in PBC, CAH, ALD and WD. C1 INH was increased in PBC, CAH, ALD, LDBO and VH. Factor B was increased in LDBO and VH and decreased in CC. In none of the patient groups was the mean C4 level increased or the mean C1 INH level decreased. All 5 indices of serum complement were lower in ascitic than nonascitic patients. Data on serum complement were similar in HBsAg positive and negative VH. Discriminant analysis facilitated separation of all the patient groups on the basis of complement data, except PBC and VA. Analysis of data using a within-group correlation matrix revealed a significant negative correlation between C4, the most discriminating variable of serum complement in CAH, and gamma-globulin concentration in CAH. The possible contribution of factors such as activation of complement, impaired hepatic synthesis of complement components, an acute phase response and cholestasis to altered serum complement profiles in different hepatobiliary diseases is discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 86474     DOI: 10.1159/000198223

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  9 in total

1.  Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality.

Authors:  C Homann; K Varming; K Høgåsen; T E Mollnes; N Graudal; A C Thomsen; P Garred
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

2.  Comparative studies on immunoglobulins, complement component (C3), albumin, and immunoglobulin A-containing circulating immune complexes in serum and bile of patients with biliary obstruction.

Authors:  G Ohshio; F Furukawa; T Manabe; T Tobe; Y Hamashima
Journal:  Dig Dis Sci       Date:  1988-05       Impact factor: 3.199

3.  Serum markers may distinguish biliary atresia from other forms of neonatal cholestasis.

Authors:  Hongtao Wang; James P Malone; Petra Erdmann Gilmore; Alan E Davis; John C Magee; R Reid Townsend; Robert O Heuckeroth
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-04       Impact factor: 2.839

4.  The complement system and systemic sclerosis.

Authors:  C Benbassat; M Schlesinger; C Luderschmidt; G Valentini; G Tirri; Y Shoenfeld
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

5.  Circulating immune complexes and complement concentrations in patients with alcoholic liver disease.

Authors:  C Gluud; H Jans
Journal:  J Clin Pathol       Date:  1982-04       Impact factor: 3.411

6.  Complement profile in primary biliary cirrhosis.

Authors:  M Schlesinger; C Benbassat; Y Shoenfeld
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

7.  Complement levels in patients with hepatic dysfunction.

Authors:  R T Ellison; C R Horsburgh; J Curd
Journal:  Dig Dis Sci       Date:  1990-02       Impact factor: 3.199

Review 8.  What makes non-cirrhotic portal hypertension a common disease in India? Analysis for environmental factors.

Authors:  Ashish Goel; Banumathi Ramakrishna; Uday Zachariah; K G Sajith; Deepak K Burad; Thomas A Kodiatte; Shyamkumar N Keshava; K A Balasubramanian; Elwyn Elias; C E Eapen
Journal:  Indian J Med Res       Date:  2019-04       Impact factor: 2.375

9.  Clinicopathological characteristics and prognosis of hepatitis B associated membranous nephropathy and idiopathic membranous nephropathy complicated with hepatitis B virus infection.

Authors:  Ruiqiang Wang; Yunqi Wu; Bowen Zheng; Xiaofeng Zhang; Dongyue An; Ningning Guo; Jin Wang; Yuanyuan Guo; Lin Tang
Journal:  Sci Rep       Date:  2021-09-15       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.